These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Razorenova OV; Castellini L; Colavitti R; Edgington LE; Nicolau M; Huang X; Bedogni B; Mills EM; Bogyo M; Giaccia AJ Mol Cell Biol; 2014 Feb; 34(4):739-51. PubMed ID: 24344197 [TBL] [Abstract][Full Text] [Related]
84. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene. Hughson MD; He Z; Liu S; Coleman J; Shingleton WB Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449 [TBL] [Abstract][Full Text] [Related]
85. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. Land SC; Tee AR J Biol Chem; 2007 Jul; 282(28):20534-43. PubMed ID: 17502379 [TBL] [Abstract][Full Text] [Related]
86. Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia. Neelam S; Brooks MM; Cammarata PR Mol Vis; 2013; 19():1-15. PubMed ID: 23335846 [TBL] [Abstract][Full Text] [Related]
87. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. Jensen RL; Gillespie D; House P; Layfield L; Shelton C J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285 [TBL] [Abstract][Full Text] [Related]
88. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Shenoy N; Pagliaro L Ann Oncol; 2016 Sep; 27(9):1685-95. PubMed ID: 27329246 [TBL] [Abstract][Full Text] [Related]
89. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression. Périgny M; Hammel P; Corcos O; Larochelle O; Giraud S; Richard S; Sauvanet A; Belghiti J; Ruszniewski P; Bedossa P; Couvelard A Am J Surg Pathol; 2009 May; 33(5):739-48. PubMed ID: 19238077 [TBL] [Abstract][Full Text] [Related]
90. β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. Dere R; Perkins AL; Bawa-Khalfe T; Jonasch D; Walker CL J Am Soc Nephrol; 2015 Mar; 26(3):553-64. PubMed ID: 25313256 [TBL] [Abstract][Full Text] [Related]
92. CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma. Schokrpur S; Hu J; Moughon DL; Liu P; Lin LC; Hermann K; Mangul S; Guan W; Pellegrini M; Xu H; Wu L Sci Rep; 2016 Jun; 6():29032. PubMed ID: 27358011 [TBL] [Abstract][Full Text] [Related]
93. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia. Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510 [TBL] [Abstract][Full Text] [Related]
94. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Pantuck AJ; An J; Liu H; Rettig MB Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166 [TBL] [Abstract][Full Text] [Related]
95. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
96. Fibrosis and hypoxia-inducible factor-1α-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors. Mangiavini L; Merceron C; Araldi E; Khatri R; Gerard-O'Riley R; Wilson TL; Sandusky G; Abadie J; Lyons KM; Giaccia AJ; Schipani E Am J Pathol; 2015 Nov; 185(11):3090-101. PubMed ID: 26348575 [TBL] [Abstract][Full Text] [Related]
97. Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits hypoxia-induced neovasculogenesis through prolyl hydroxylase, von Hippel-Lindau-dependent pathway. Li CH; Liao PL; Yang YT; Huang SH; Lin CH; Cheng YW; Kang JJ Arch Toxicol; 2014 Mar; 88(3):659-71. PubMed ID: 24292262 [TBL] [Abstract][Full Text] [Related]
98. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin. Kumar V; Kaushik V; Kumar S; Levkovich SA; Gupta P; Laor Bar-Yosef D; Gazit E; Segal D Biochem Biophys Res Commun; 2024 Jan; 690():149250. PubMed ID: 38039781 [TBL] [Abstract][Full Text] [Related]
99. Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Champion KJ; Guinea M; Dammai V; Hsu T Cancer Res; 2008 Jun; 68(12):4649-57. PubMed ID: 18559510 [TBL] [Abstract][Full Text] [Related]
100. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells. Harten SK; Esteban MA; Shukla D; Ashcroft M; Maxwell PH Mol Cancer; 2011 Jul; 10():89. PubMed ID: 21791076 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]